Insmed Brensocatib Shows Consistent Efficacy and Safety in 3 Respiratory Studies

 Insmed Presented 11 Abstracts at ATS 2025 from Across Its Respiratory Portfolio, Including Data on ARIKAYCE®, TPIP and Health Economics and Outcomes Research   —

 Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, presented 11 new abstracts at the American Thoracic Society (ATS) 2025 International Conference, which took place May 18-21 in San Francisco, including three prespecified subgroup analyses from the Phase 3 ASPEN trial of brensocatib in non-cystic fibrosis bronchiectasis (NCFBE), signaling the consistency of efficacy and safety outcomes across diverse clinical profiles.

"It is critical that we understand not only how brensocatib performed across the full ASPEN population, but also how it works within individual subgroups," said James D. Chalmers, MBChB, Ph.D., Professor of Respiratory Research, University of Dundee. "These new analyses offer evidence of consistent efficacy and safety in key patient types—including adolescents aged 12 and older, those receiving macrolide therapy, and individuals with various blood eosinophil levels—reinforcing the potential of brensocatib as a foundational treatment for this complex and heterogeneous disease."

https://finance.yahoo.com/news/brensocatib-shows-consistent-efficacy-safety-200500821.html